ArticleAmerican journal of translational research2016
Wallichinine reverses ABCB1-mediated cancer multidrug resistance.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- ML210 Antagonizes ABCB1- Not ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.Biomedicines · 2025Article
- Celastrol Inhibits the Growth of Ovarian Cancer CellsFrontiers in oncology · 2019Article
- Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma.Frontiers in oncology · 2019Article
- Survivin Promotes Piperlongumine Resistance in Ovarian Cancer.Frontiers in oncology · 2019Article
- Molecular Mechanism of Matrine fromBioMed research international · 2019Article
- Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer.Frontiers in oncology · 2019Article
- YM155 enhances docetaxel efficacy in ovarian cancer.American journal of translational research · 2018Article
- Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancerAmerican journal of translational research · 2018Article
- Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.American journal of translational research · 2017Article
- Caragaphenol a induces reactive oxygen species related apoptosis in human gastric cancer cells.American journal of translational research · 2017Article
- Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.American journal of translational research · 2016Article
- Volasertib suppresses the growth of human hepatocellular carcinomaAmerican journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of ABCB1 in cancer cells is one of the main reasons of cancer multidrug resistance (MDR). Wallichinine is a compound isolated from piper wallichii and works as an antagonist of platelet activiating factor receptor to inhibit the gathering of blood platelet. In this study, we investigate the effect of wallichinine on cancer MDR mediated by ABCB1 transporter. Wallichinine significantly potentiates the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in ABCB1 overexpressing cancer cells. Furthermore, wallichinine do not alter the sensitivity of non-ABCB1 substrate cisplatin. Mechanistically, wallichinine blocks the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1. The predicted binding mode shows the hydrophobic interactions of wallichinine within the large drug binding cavity of ABCB1. At all, our study of the interaction of wallichinine with ABCB1 presented herein provides valuable clues for the development of novel MDR reversal reagents from natural products.
Indexed as
Identifiers
27508017PMC4969433W2501724362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.